Kymera Therapeutics, Inc. Common Stock insider trading
KYMRfinancial statementsForm 4 filings on EDGAR381 transactions since Nov 9, 2024
From August 12, 2026 to November 9, 2026, 0 insiders at Kymera Therapeutics, Inc. Common Stock bought $0 of stock in the open market, and 2 sold $4M. Officers and directors accounted for $0 of purchases and $4M of sales. The last reported transaction was an option exercise by Mainolfi Nello on October 1, 2026.
The answer card and chart use the same period. Change the range above the chart to update both. Form 4 filings through October 1, 2026; awards, option exercises, tax withholding and gifts are excluded from these totals.
Stock price and insider activity
Daily price candles with insider purchases and sales directly beneath them on the same timeline. Bars show individual days; totals sum all days in the selected period.
Bought $0Sold $4MAug 12, 2026 – Nov 9, 2026
purchases above zero; sales below. Both use the transaction date and the same dollar scale. Hover, tap, or use arrow keys to inspect a date. Awards, exercises, tax withholding and gifts are excluded.
Dates with prices or insider activity are spaced evenly; empty weekends and holidays are omitted. Prices through Nov 6, 2026. Insider data through Nov 9, 2026. Prices are adjusted for splits; transaction values are reported dollars.
Every transaction
381 transactions from November 9, 2024 to November 9, 2026, newest first. Open-market purchases and sales are coloured; awards, exercises, tax withholding and gifts are grey and not counted.
| Traded | Insider | Role | Transaction | Shares | Price | Value | Held after | Filed |
|---|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | Mainolfi Nello | Chief Executive Officer, Director | option exercise | 30,000 | $2.08 | $62K | 696,568 | Oct 1, 2026 |
| Oct 1, 2026 | Mainolfi Nello | Chief Executive Officer, Director | open-market sale10b5-1 | 3,525 | $111.44 | $393K | 693,043 | Oct 1, 2026 |
| Oct 1, 2026 | Mainolfi Nello | Chief Executive Officer, Director | open-market sale10b5-1 | 5,506 | $112.42 | $619K | 687,537 | Oct 1, 2026 |
| Oct 1, 2026 | Mainolfi Nello | Chief Executive Officer, Director | open-market sale10b5-1 | 4,876 | $113.24 | $552K | 682,661 | Oct 1, 2026 |
| Oct 1, 2026 | Mainolfi Nello | Chief Executive Officer, Director | open-market sale10b5-1 | 7,601 | $114.43 | $870K | 675,060 | Oct 1, 2026 |
| Oct 1, 2026 | Mainolfi Nello | Chief Executive Officer, Director | open-market sale10b5-1 | 8,230 | $115.40 | $950K | 666,830 | Oct 1, 2026 |
| Oct 1, 2026 | Mainolfi Nello | Chief Executive Officer, Director | open-market sale10b5-1 | 262 | $116.12 | $30K | 666,568 | Oct 1, 2026 |
| Sep 4, 2026 | Adams Brian | Chief Legal Officer | open-market sale | 1,209 | $115.55 | $140K | 55,416 | Sep 4, 2026 |
| Sep 4, 2026 | Adams Brian | Chief Legal Officer | open-market sale | 3,025 | $116.81 | $353K | 52,391 | Sep 4, 2026 |
| Sep 4, 2026 | Adams Brian | Chief Legal Officer | open-market sale | 2,137 | $117.57 | $251K | 50,254 | Sep 4, 2026 |
| Jul 27, 2026 | Rooney Terence | Chief Medical Officer | award | 38,000 | $0.00 | — | 38,000 | Jul 27, 2026 |
| Jul 7, 2026 | Mainolfi Nello | Chief Executive Officer, Director | option exercise | 50,000 | $2.08 | $104K | 716,568 | Jul 7, 2026 |
| Jul 7, 2026 | Mainolfi Nello | Chief Executive Officer, Director | open-market sale10b5-1 | 50,000 | $119.00 | $6M | 666,568 | Jul 7, 2026 |
| Jul 1, 2026 | Goodman Noah | Chief Business Officer | open-market sale10b5-1 | 3,389 | $114.29 | $387K | 47,179 | Jul 2, 2026 |
| Jul 1, 2026 | Mainolfi Nello | Chief Executive Officer, Director | option exercise | 80,000 | $2.08 | $166K | 746,568 | Jul 2, 2026 |
| Jul 1, 2026 | Mainolfi Nello | Chief Executive Officer, Director | open-market sale10b5-1 | 1,883 | $112.80 | $212K | 744,685 | Jul 2, 2026 |
| Jul 1, 2026 | Mainolfi Nello | Chief Executive Officer, Director | open-market sale10b5-1 | 6,626 | $113.98 | $755K | 738,059 | Jul 2, 2026 |
| Jul 1, 2026 | Mainolfi Nello | Chief Executive Officer, Director | open-market sale10b5-1 | 24,105 | $114.96 | $3M | 713,954 | Jul 2, 2026 |
| Jul 1, 2026 | Mainolfi Nello | Chief Executive Officer, Director | open-market sale10b5-1 | 44,050 | $115.69 | $5M | 669,904 | Jul 2, 2026 |
| Jul 1, 2026 | Mainolfi Nello | Chief Executive Officer, Director | open-market sale10b5-1 | 3,336 | $116.56 | $389K | 666,568 | Jul 2, 2026 |
| Jun 30, 2026 | Jacobs Bruce N. | Chief Financial Officer | option exercise | 61,378 | $5.33 | $327K | 321,992 | Jul 2, 2026 |
| Jun 30, 2026 | Jacobs Bruce N. | Chief Financial Officer | open-market sale10b5-1 | 1,500 | $110.54 | $166K | 320,492 | Jul 2, 2026 |
| Jun 30, 2026 | Jacobs Bruce N. | Chief Financial Officer | open-market sale10b5-1 | 1,700 | $111.57 | $190K | 318,792 | Jul 2, 2026 |
| Jun 30, 2026 | Jacobs Bruce N. | Chief Financial Officer | open-market sale10b5-1 | 1,100 | $112.79 | $124K | 317,692 | Jul 2, 2026 |
| Jun 30, 2026 | Jacobs Bruce N. | Chief Financial Officer | open-market sale10b5-1 | 4,110 | $114.19 | $469K | 313,582 | Jul 2, 2026 |
| Jun 30, 2026 | Jacobs Bruce N. | Chief Financial Officer | open-market sale10b5-1 | 51,375 | $114.77 | $6M | 262,207 | Jul 2, 2026 |
| Jun 30, 2026 | Jacobs Bruce N. | Chief Financial Officer | open-market sale10b5-1 | 7,971 | $115.82 | $923K | 254,236 | Jul 2, 2026 |
| Jun 30, 2026 | Jacobs Bruce N. | Chief Financial Officer | open-market sale10b5-1 | 6,153 | $116.99 | $720K | 248,083 | Jul 2, 2026 |
| Jun 30, 2026 | Jacobs Bruce N. | Chief Financial Officer | open-market sale10b5-1 | 3,200 | $117.70 | $377K | 244,883 | Jul 2, 2026 |
| Jun 29, 2026 | Booth Bruce | Director | open-market sale10b5-1indirect | 5,549 | $105.78 | $587K | 2M | Jul 2, 2026 |
| Jun 29, 2026 | Booth Bruce | Director | open-market sale10b5-1indirect | 14,798 | $106.63 | $2M | 2M | Jul 2, 2026 |
| Jun 29, 2026 | Booth Bruce | Director | open-market sale10b5-1indirect | 19,419 | $107.76 | $2M | 2M | Jul 2, 2026 |
| Jun 29, 2026 | Booth Bruce | Director | open-market sale10b5-1indirect | 10,848 | $108.28 | $1M | 2M | Jul 2, 2026 |
| Jun 29, 2026 | Booth Bruce | Director | open-market sale10b5-1indirect | 7,968 | $109.75 | $874K | 2M | Jul 2, 2026 |
| Jun 29, 2026 | Booth Bruce | Director | open-market sale10b5-1indirect | 7,723 | $110.67 | $855K | 2M | Jul 2, 2026 |
| Jun 29, 2026 | Booth Bruce | Director | open-market sale10b5-1indirect | 934 | $111.20 | $104K | 2M | Jul 2, 2026 |
| Jun 29, 2026 | Booth Bruce | Director | open-market sale10b5-1indirect | 770 | $105.78 | $81K | 471,497 | Jul 2, 2026 |
| Jun 29, 2026 | Booth Bruce | Director | open-market sale10b5-1indirect | 2,133 | $106.63 | $227K | 469,364 | Jul 2, 2026 |
| Jun 29, 2026 | Booth Bruce | Director | open-market sale10b5-1indirect | 2,698 | $107.76 | $291K | 466,666 | Jul 2, 2026 |
| Jun 29, 2026 | Booth Bruce | Director | open-market sale10b5-1indirect | 1,498 | $108.28 | $162K | 465,168 | Jul 2, 2026 |
| Jun 29, 2026 | Booth Bruce | Director | open-market sale10b5-1indirect | 1,104 | $109.75 | $121K | 464,064 | Jul 2, 2026 |
| Jun 29, 2026 | Booth Bruce | Director | open-market sale10b5-1indirect | 1,078 | $110.67 | $119K | 462,986 | Jul 2, 2026 |
| Jun 29, 2026 | Booth Bruce | Director | open-market sale10b5-1indirect | 130 | $111.20 | $14K | 462,856 | Jul 2, 2026 |
| Jun 29, 2026 | Booth Bruce | Director | open-market sale10b5-1indirect | 10,658 | $108.28 | $1M | 2M | Jun 30, 2026 |
| Jun 29, 2026 | Booth Bruce | Director | open-market sale10b5-1indirect | 7,833 | $109.75 | $860K | 2M | Jun 30, 2026 |
| Jun 29, 2026 | Booth Bruce | Director | open-market sale10b5-1indirect | 7,602 | $110.67 | $841K | 2M | Jun 30, 2026 |
| Jun 29, 2026 | Booth Bruce | Director | open-market sale10b5-1indirect | 907 | $111.20 | $101K | 2M | Jun 30, 2026 |
| Jun 29, 2026 | Booth Bruce | Director | open-market sale10b5-1indirect | 1,688 | $108.28 | $183K | 464,389 | Jun 30, 2026 |
| Jun 29, 2026 | Booth Bruce | Director | open-market sale10b5-1indirect | 1,239 | $109.75 | $136K | 463,150 | Jun 30, 2026 |
| Jun 29, 2026 | Booth Bruce | Director | open-market sale10b5-1indirect | 1,199 | $110.67 | $133K | 461,951 | Jun 30, 2026 |
Who the insiders are
Everyone who reported a transaction since November 9, 2024, by open-market value over twelve months. Shares held are after the insider’s latest directly held transaction.
| Insider | Role | Last transaction | Kind | Shares held | Bought, 12 months | Sold, 12 months | Sales under a plan |
|---|---|---|---|---|---|---|---|
| Booth Bruce | Director | Jun 29, 2026 | open-market sale | 11,741 | — | $226M (160) | 146 of 160 |
| Bvf Partners L P/il | Director | Jun 26, 2026 | open-market sale | 2M | — | $174M (4) | 0 of 4 |
| Baker Felix | Director, 10% owner | Dec 11, 2025 | open-market buy | — | $172M (2) | — | — |
| Mainolfi Nello | Chief Executive Officer, Director | Oct 1, 2026 | option exercise | 696,568 | — | $35M (23) | 23 of 23 |
| Chadwick Jeremy G | Chief Operating Officer | May 27, 2026 | open-market sale | 44,618 | — | $16M (29) | 22 of 29 |
| Jacobs Bruce N. | Chief Financial Officer | Jun 30, 2026 | option exercise | 321,992 | — | $10M (15) | 8 of 15 |
| Gollob Jared | Chief Medical Officer | Mar 4, 2026 | open-market sale | 117,581 | — | $5M (13) | 6 of 13 |
| Esposito Pamela | Director | May 19, 2026 | option exercise | 1,000 | — | $3M (12) | 12 of 12 |
| Goodman Noah | Chief Business Officer | Jul 1, 2026 | open-market sale | 47,179 | — | $2M (9) | 9 of 9 |
| Ridloff Elena | Director | May 11, 2026 | option exercise | 3,000 | — | $1M (4) | 4 of 4 |
| Adams Brian | Chief Legal Officer | Sep 4, 2026 | open-market sale | 55,416 | — | $744K (3) | 0 of 3 |
| Albers Jeffrey W. | Director | Dec 8, 2025 | open-market sale | 0 | — | $449K (2) | 2 of 2 |
| Chiniara Ellen | Chief Legal Officer | Mar 3, 2025 | open-market sale | 80,085 | — | — | — |
| Biotechnology Value Trading Fund OS LP | Director | Jun 30, 2025 | open-market buy | 353,412 | — | — | — |
| Baker Bros. Advisors (GP) LLC | Director | Jun 30, 2025 | open-market buy | — | — | — | — |
| Rooney Terence | Chief Medical Officer | Jul 27, 2026 | award | 38,000 | — | — | — |
Questions
Are Kymera Therapeutics, Inc. Common Stock insiders buying or selling?
Over the twelve months to November 9, 2026, 11 insiders at Kymera Therapeutics, Inc. Common Stock sold $473M of stock in the open market, all by officers and directors, and 1 insider bought $172M, all by officers and directors. Net, insiders sold $301M. Only open-market purchases and sales are counted.
Who sold the most Kymera Therapeutics, Inc. Common Stock stock in the last year?
Booth Bruce (Director) sold $226M in 160 open-market sales over the twelve months to November 9, 2026.
Do Kymera Therapeutics, Inc. Common Stock executives sell under 10b5-1 plans?
232 of the 274 open-market sales in the last twelve months (85%) were reported as made under a Rule 10b5-1 trading plan, set up in advance. A sale under a plan is still counted as a sale.
What counts as insider buying here?
Only open-market purchases (Form 4 code P) and sales (code S) by officers, directors and 10% owners. Stock awards, option exercises, shares withheld for tax and gifts are listed in the table but never counted as buying or selling.
More on Kymera Therapeutics, Inc. Common Stock
- Kymera Therapeutics, Inc. Common Stock financial statements
- 1 tracked fund holding KYMR
- Insider buying and selling across all companies
- These transactions as JSON
From Form 4, 4/A and 5 filings with the SEC. A record of insider transactions, not a recommendation.